These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 35598501)

  • 1. A randomized, open-label pilot trial of selective serotonin reuptake inhibitors on neuropsychological functions in patients with obsessive compulsive disorder.
    Brar J; Sidana A; Chauhan N; Bajaj MK
    J Psychiatr Res; 2022 Jul; 151():439-444. PubMed ID: 35598501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Memantine augmentation of sertraline in the treatment of symptoms and executive function among patients with obsessive-compulsive disorder: A double-blind placebo-controlled, randomized clinical trial.
    Askari S; Mokhtari S; Shariat SV; Shariati B; Yarahmadi M; Shalbafan M
    BMC Psychiatry; 2022 Jan; 22(1):34. PubMed ID: 35022014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A study of cognitive function in treatment-refractory obsessive-compulsive disorder treated with capsulotomy.
    Gong F; Li P; Li B; Zhang S; Zhang X; Yang S; Liu H; Wang W
    J Neurosurg; 2018 Feb; 128(2):583-595. PubMed ID: 28338440
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Granisetron-mediated augmentation of sertraline therapeutic effect in obsessive-compulsive disorder: a double-blind placebo-controlled, randomized clinical trial.
    Ghobadian A; Mokhtari S; Shariati B; Kamalzadeh L; Shati M; Eftekhar Ardebili M; Yarahmadi M; Shalbafan M
    BMC Pharmacol Toxicol; 2022 Sep; 23(1):73. PubMed ID: 36167636
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early onset of response with selective serotonin reuptake inhibitors in obsessive-compulsive disorder: a meta-analysis.
    Issari Y; Jakubovski E; Bartley CA; Pittenger C; Bloch MH
    J Clin Psychiatry; 2016 May; 77(5):e605-11. PubMed ID: 27249090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amantadine as adjuvant therapy in the treatment of moderate to severe obsessive-compulsive disorder: A double-blind randomized trial with placebo control.
    Naderi S; Faghih H; Aqamolaei A; Mortazavi SH; Mortezaei A; Sahebolzamani E; Rezaei F; Akhondzadeh S
    Psychiatry Clin Neurosci; 2019 Apr; 73(4):169-174. PubMed ID: 30488617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of factor-analyzed symptom dimensions to predict outcome with serotonin reuptake inhibitors and placebo in the treatment of obsessive-compulsive disorder.
    Mataix-Cols D; Rauch SL; Manzo PA; Jenike MA; Baer L
    Am J Psychiatry; 1999 Sep; 156(9):1409-16. PubMed ID: 10484953
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intact short-term memory and impaired executive functions in obsessive compulsive disorder.
    Demeter G; Racsmány M; Csigó K; Harsányi A; Németh A; Döme L
    Ideggyogy Sz; 2013 Jan; 66(1-2):35-41. PubMed ID: 23607228
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cognitive-behavioral therapy as an adjunct to serotonin reuptake inhibitors in obsessive-compulsive disorder: an open trial.
    Simpson HB; Gorfinkle KS; Liebowitz MR
    J Clin Psychiatry; 1999 Sep; 60(9):584-90. PubMed ID: 10520976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuropsychological performance in medicated vs. unmedicated patients with obsessive-compulsive disorder.
    Mataix-Cols D; Alonso P; Pifarré J; Menchón JM; Vallejo J
    Psychiatry Res; 2002 Apr; 109(3):255-64. PubMed ID: 11959362
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic and pharmacogenetic study of glutamate transporter (SLC1A1) in Iranian patients with obsessive-compulsive disorder.
    Abdolhosseinzadeh S; Sina M; Ahmadiani A; Asadi S; Shams J
    J Clin Pharm Ther; 2019 Feb; 44(1):39-48. PubMed ID: 30315580
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Riluzole in augmentation of fluvoxamine for moderate to severe obsessive-compulsive disorder: Randomized, double-blind, placebo-controlled study.
    Emamzadehfard S; Kamaloo A; Paydary K; Ahmadipour A; Zeinoddini A; Ghaleiha A; Mohammadinejad P; Zeinoddini A; Akhondzadeh S
    Psychiatry Clin Neurosci; 2016 Aug; 70(8):332-41. PubMed ID: 27106362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Escitalopram in the treatment of patients with schizophrenia and obsessive-compulsive disorder: an open-label, prospective study.
    Stryjer R; Dambinsky Y; Timinsky I; Green T; Kotler M; Weizman A; Spivak B
    Int Clin Psychopharmacol; 2013 Mar; 28(2):96-8. PubMed ID: 23211492
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: a placebo-controlled trial.
    Bystritsky A; Ackerman DL; Rosen RM; Vapnik T; Gorbis E; Maidment KM; Saxena S
    J Clin Psychiatry; 2004 Apr; 65(4):565-8. PubMed ID: 15119922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized, Double-Blind, Placebo-Controlled Trial of N-Acetylcysteine Augmentation for Treatment-Resistant Obsessive-Compulsive Disorder.
    Costa DLC; Diniz JB; Requena G; Joaquim MA; Pittenger C; Bloch MH; Miguel EC; Shavitt RG
    J Clin Psychiatry; 2017 Jul; 78(7):e766-e773. PubMed ID: 28617566
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Obsessive-compulsive disorder: a 3-year prospective follow-up study of patients treated with serotonin reuptake inhibitors OCD follow-up study.
    Catapano F; Perris F; Masella M; Rossano F; Cigliano M; Magliano L; Maj M
    J Psychiatr Res; 2006 Sep; 40(6):502-10. PubMed ID: 16904424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of selective serotonin reuptake inhibitors on thought-action fusion, metacognitions, and thought suppression in obsessive-compulsive disorder.
    Besiroglu L; Çetinkaya N; Selvi Y; Atli A
    Compr Psychiatry; 2011; 52(5):556-61. PubMed ID: 21109243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuropsychological functioning in youth with obsessive compulsive disorder: an examination of executive function and memory impairment.
    Lewin AB; Larson MJ; Park JM; McGuire JF; Murphy TK; Storch EA
    Psychiatry Res; 2014 Apr; 216(1):108-15. PubMed ID: 24508366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Double-blind study of dextroamphetamine versus caffeine augmentation for treatment-resistant obsessive-compulsive disorder.
    Koran LM; Aboujaoude E; Gamel NN
    J Clin Psychiatry; 2009 Nov; 70(11):1530-5. PubMed ID: 19573497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cognitive-behavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: a randomized clinical trial.
    Simpson HB; Foa EB; Liebowitz MR; Huppert JD; Cahill S; Maher MJ; McLean CP; Bender J; Marcus SM; Williams MT; Weaver J; Vermes D; Van Meter PE; Rodriguez CI; Powers M; Pinto A; Imms P; Hahn CG; Campeas R
    JAMA Psychiatry; 2013 Nov; 70(11):1190-9. PubMed ID: 24026523
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.